{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:30Z","timestamp":1790401770840,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.1038\/s41416-025-03218-8","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:41:24Z","timestamp":1761662484000},"page":"72-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL\/STAT3\/ABCG1 in gastric cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Tae Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jeong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-5597","authenticated-orcid":false,"given":"In-Hye","family":"Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen Thanh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2377","authenticated-orcid":false,"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-5363","authenticated-orcid":false,"given":"Hoon","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"3218_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3218_CR2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5230\/jgc.2022.22.e21","volume":"22","author":"SH Park","year":"2022","unstructured":"Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea Central Cancer Registry Data (1999-2019). J Gastric Cancer. 2022;22:160\u20138.","journal-title":"J Gastric Cancer"},{"key":"3218_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5230\/jgc.2025.25.e11","volume":"25","author":"IH Kim","year":"2025","unstructured":"Kim IH, Kang SJ, Choi W, Seo AN, Eom BW, et al. Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-Based, Multidisciplinary Approach (Update of 2022 Guideline). J Gastric Cancer. 2025;25:5\u2013114.","journal-title":"J Gastric Cancer"},{"key":"3218_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer A","year":"2023","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"3218_CR5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37\u201341.","journal-title":"Cancer"},{"key":"3218_CR6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/annonc\/mdx275","volume":"28","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, et al. A phase III trial comparing oral S-1\/cisplatin and intravenous 5-fluorouracil\/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017;28:2142\u20138.","journal-title":"Ann Oncol"},{"key":"3218_CR7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"3218_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"3218_CR9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769\u201392.","journal-title":"Cancers"},{"key":"3218_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000086183","volume":"14","author":"YA Luqmani","year":"2005","unstructured":"Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005;14:35\u201348.","journal-title":"Med Princ Pract"},{"key":"3218_CR11","doi-asserted-by":"crossref","first-page":"629266","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"LY Li","year":"2020","unstructured":"Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharm. 2020;11:629266.","journal-title":"Front Pharm"},{"key":"3218_CR12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957\u201367.","journal-title":"Cell"},{"key":"3218_CR13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0026-895X(25)08713-9","volume":"49","author":"EG Schuetz","year":"1996","unstructured":"Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharm. 1996;49:311\u20138.","journal-title":"Mol Pharm"},{"key":"3218_CR14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/87912","volume":"7","author":"TW Synold","year":"2001","unstructured":"Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584\u201390.","journal-title":"Nat Med"},{"key":"3218_CR15","doi-asserted-by":"crossref","first-page":"11026","DOI":"10.1073\/pnas.0914295107","volume":"107","author":"KD Grugan","year":"2010","unstructured":"Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci USA. 2010;107:11026\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3218_CR16","volume":"7","author":"R Kanzaki","year":"2017","unstructured":"Kanzaki R, Naito H, Kise K, Takara K, Eino D, Minami M, et al. Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy. Sci Rep. 2017;7:10613.","journal-title":"Sci Rep"},{"key":"3218_CR17","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1084\/jem.20131195","volume":"210","author":"F Lotti","year":"2013","unstructured":"Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013;210:2851\u201372.","journal-title":"J Exp Med"},{"key":"3218_CR18","volume":"2019","author":"IH Ham","year":"2019","unstructured":"Ham IH, Lee D, Hur H. Role of cancer-associated fibroblast in gastric cancer progression and resistance to treatments. J Oncol. 2019;2019:6270784.","journal-title":"J Oncol"},{"key":"3218_CR19","doi-asserted-by":"crossref","unstructured":"Ham IH, Lee D, Hur H. Cancer-associated fibroblast-induced resistance to chemotherapy and radiotherapy in gastrointestinal cancers. Cancers. 2021;13:1172.","DOI":"10.3390\/cancers13051172"},{"key":"3218_CR20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","volume":"23","author":"CA Bae","year":"2020","unstructured":"Bae CA, Ham IH, Oh HJ, Lee D, Woo J, Son SY, et al. Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer. 2020;23:824\u201336.","journal-title":"Gastric Cancer"},{"key":"3218_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","volume":"100","author":"RM Linger","year":"2008","unstructured":"Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35\u201383.","journal-title":"Adv Cancer Res"},{"key":"3218_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/mc.20211","volume":"46","author":"T Sawabu","year":"2007","unstructured":"Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 2007;46:155\u201364.","journal-title":"Mol Carcinog"},{"key":"3218_CR23","doi-asserted-by":"crossref","unstructured":"Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P, et al. AXL receptor in breast cancer: molecular involvement and therapeutic limitations. Int J Mol Sci. 2020;21:8419.","DOI":"10.3390\/ijms21228419"},{"key":"3218_CR24","volume":"12","author":"YB Sang","year":"2022","unstructured":"Sang YB, Kim JH, Kim CG, Hong MH, Kim HR, Cho BC, et al. The development of AXL inhibitors in lung cancer: recent progress and challenges. Front Oncol. 2022;12:811247.","journal-title":"Front Oncol"},{"key":"3218_CR25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","volume":"25","author":"S Bhalla","year":"2023","unstructured":"Bhalla S, Gerber DE. AXL inhibitors: status of clinical development. Curr Oncol Rep. 2023;25:521\u20139.","journal-title":"Curr Oncol Rep"},{"key":"3218_CR26","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/s41375-023-02029-1","volume":"37","author":"AS Kubasch","year":"2023","unstructured":"Kubasch AS, Peterlin P, Cluzeau T, Gotze KS, Sockel K, Teipel R, et al. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia. 2023;37:2309\u201313.","journal-title":"Leukemia"},{"key":"3218_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58179-6","volume":"16","author":"S Loges","year":"2025","unstructured":"Loges S, Heuser M, Chromik J, Sutamtewagul G, Kapp-Schwoerer S, Crugnola M, et al. Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b\/2a trial. Nat Commun. 2025;16:2846.","journal-title":"Nat Commun"},{"key":"3218_CR28","doi-asserted-by":"crossref","unstructured":"Yan S, Vandewalle N, De Beule N, Faict S, Maes K, De Bruyne E, et al. AXL receptor tyrosine kinase as a therapeutic target in hematological malignancies: focus on multiple myeloma. Cancers. 2019;11:1727.","DOI":"10.3390\/cancers11111727"},{"key":"3218_CR29","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1021\/acs.jmedchem.6b00608","volume":"59","author":"L Tan","year":"2016","unstructured":"Tan L, Zhang Z, Gao D, Luo J, Tu ZC, Li Z, et al. 4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors. J Med Chem. 2016;59:6807\u201325.","journal-title":"J Med Chem"},{"key":"3218_CR30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 2023;23:762\u201379.","journal-title":"Nat Rev Cancer"},{"key":"3218_CR31","volume":"12","author":"H Xiao","year":"2021","unstructured":"Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharm. 2021;12:648407.","journal-title":"Front Pharm"},{"key":"3218_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cmet.2005.01.002","volume":"1","author":"MA Kennedy","year":"2005","unstructured":"Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1:121\u201331.","journal-title":"Cell Metab"},{"key":"3218_CR33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbalip.2009.01.007","volume":"1791","author":"PT Tarr","year":"2009","unstructured":"Tarr PT, Tarling EJ, Bojanic DD, Edwards PA, Baldan A. Emerging new paradigms for ABCG transporters. Biochim Biophys Acta. 2009;1791:584\u201393.","journal-title":"Biochim Biophys Acta"},{"key":"3218_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6480-9","volume":"20","author":"X Liao","year":"2020","unstructured":"Liao X, Song G, Xu Z, Bu Y, Chang F, Jia F, et al. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer. 2020;20:31.","journal-title":"BMC Cancer"},{"key":"3218_CR35","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.7150\/thno.29463","volume":"9","author":"J Zhan","year":"2019","unstructured":"Zhan J, Wang P, Li S, Song J, He H, Wang Y, et al. HOXB13 networking with ABCG1\/EZH2\/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients. Theranostics. 2019;9:2084\u201399.","journal-title":"Theranostics"},{"key":"3218_CR36","volume":"10","author":"A Po","year":"2020","unstructured":"Po A, Citarella A, Catanzaro G, Besharat ZM, Trocchianesi S, Gianno F, et al. Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells. Sci Rep. 2020;10:13988.","journal-title":"Sci Rep"},{"key":"3218_CR37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10120-016-0669-2","volume":"20","author":"D Lee","year":"2017","unstructured":"Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer. 2017;20:591\u2013601.","journal-title":"Gastric Cancer"},{"key":"3218_CR38","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1158\/1078-0432.CCR-21-0792","volume":"27","author":"HY Jeong","year":"2021","unstructured":"Jeong HY, Ham IH, Lee SH, Ryu D, Son SY, Han SU, et al. Spatially distinct reprogramming of the tumor microenvironment based on tumor invasion in diffuse-type gastric cancers. Clin Cancer Res. 2021;27:6529\u201342.","journal-title":"Clin Cancer Res"},{"key":"3218_CR39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12:670\u201391.","journal-title":"Cancer Discov"},{"key":"3218_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33:463\u201379.e10.","journal-title":"Cancer Cell"},{"key":"3218_CR41","volume":"18","author":"IH Ham","year":"2019","unstructured":"Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM, Choi KS, et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18:68.","journal-title":"Mol Cancer"},{"key":"3218_CR42","doi-asserted-by":"crossref","unstructured":"Ham IH, Wang L, Lee D, Woo J, Kim TH, Jeong HY, et al. Curcumin inhibits the cancer\u2011associated fibroblast\u2011derived chemoresistance of gastric cancer through the suppression of the JAK\/STAT3 signaling pathway. Int J Oncol. 2022;61:85.","DOI":"10.3892\/ijo.2022.5375"},{"key":"3218_CR43","volume":"13","author":"AST Engelsen","year":"2022","unstructured":"Engelsen AST, Lotsberg ML, Abou Khouzam R, Thiery JP, Lorens JB, Chouaib S, et al. Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition. Front Immunol. 2022;13:869676.","journal-title":"Front Immunol"},{"key":"3218_CR44","doi-asserted-by":"crossref","unstructured":"Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers. 2016;8:103.","DOI":"10.3390\/cancers8110103"},{"key":"3218_CR45","doi-asserted-by":"crossref","unstructured":"Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF. The role of the receptor tyrosine kinase Axl in carcinogenesis and development of therapeutic resistance: an overview of molecular mechanisms and future applications. Cancers. 2021;13:1521.","DOI":"10.3390\/cancers13071521"},{"key":"3218_CR46","volume":"9","author":"L Gao","year":"2023","unstructured":"Gao L, Tong S, Liu J, Cai J, Ye Z, Zhou L, et al. TMEM2 induces epithelial-mesenchymal transition and promotes resistance to temozolomide in GBM cells. Heliyon. 2023;9:e16559.","journal-title":"Heliyon"},{"key":"3218_CR47","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-391","volume":"12","author":"L Flamant","year":"2012","unstructured":"Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, et al. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 2012;12:391.","journal-title":"BMC Cancer"},{"key":"3218_CR48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1244740","volume":"13","author":"GA Herrera-Quiterio","year":"2023","unstructured":"Herrera-Quiterio GA, Encarnacion-Guevara S. The transmembrane proteins (TMEM) and their role in cell proliferation, migration, invasion, and epithelial-mesenchymal transition in cancer. Front Oncol. 2023;13:1244740.","journal-title":"Front Oncol"},{"key":"3218_CR49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4143\/crt.2018.031","volume":"51","author":"J Ma","year":"2019","unstructured":"Ma J, Song X, Xu X, Mou Y. Cancer-associated fibroblasts promote the chemo-resistance in gastric cancer through secreting IL-11 targeting JAK\/STAT3\/Bcl2 pathway. Cancer Res Treat. 2019;51:194\u2013210.","journal-title":"Cancer Res Treat"},{"key":"3218_CR50","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-16-1201","volume":"76","author":"L Ireland","year":"2016","unstructured":"Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76:6851\u201363.","journal-title":"Cancer Res"},{"key":"3218_CR51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s40425-019-0814-7","volume":"7","author":"J Ma","year":"2019","unstructured":"Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, et al. PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7:331.","journal-title":"J Immunother Cancer"},{"key":"3218_CR52","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107291","volume":"182","author":"S Bhalla","year":"2023","unstructured":"Bhalla S, Fattah FJ, Ahn C, Williams J, Macchiaroli A, Padro J, et al. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 2023;182:107291.","journal-title":"Lung Cancer"},{"key":"3218_CR53","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","volume":"70","author":"SJ Holland","year":"2010","unstructured":"Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010;70:1544\u201354.","journal-title":"Cancer Res"},{"key":"3218_CR54","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14:769\u201385.","journal-title":"Nat Rev Cancer"},{"key":"3218_CR55","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1038\/sj.onc.1201123","volume":"14","author":"J Braunger","year":"1997","unstructured":"Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A, et al. Intracellular signaling of the Ufo\/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene. 1997;14:2619\u201331.","journal-title":"Oncogene"},{"key":"3218_CR56","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3218_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","volume":"30","author":"L Yvan-Charvet","year":"2010","unstructured":"Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30:139\u201343.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3218_CR58","doi-asserted-by":"crossref","unstructured":"Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, et al. ABC transporters and their role in the neoadjuvant treatment of esophageal cancer. Int J Mol Sci. 2018;19:868.","DOI":"10.3390\/ijms19030868"},{"key":"3218_CR59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1756-8722-6-49","volume":"6","author":"L Huang","year":"2013","unstructured":"Huang L, Perrault C, Coelho-Martins J, Hu C, Dulong C, Varna M, et al. Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. J Hematol Oncol. 2013;6:49.","journal-title":"J Hematol Oncol"},{"key":"3218_CR60","doi-asserted-by":"crossref","unstructured":"Tanaka M, Siemann DW. Gas6\/Axl signaling pathway in the tumor immune microenvironment. Cancers. 2020;12:1850.","DOI":"10.3390\/cancers12071850"},{"key":"3218_CR61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.ircmb.2020.09.011","volume":"357","author":"V Gadiyar","year":"2020","unstructured":"Gadiyar V, Patel G, Davra V. Immunological role of TAM receptors in the cancer microenvironment. Int Rev Cell Mol Biol. 2020;357:57\u201379.","journal-title":"Int Rev Cell Mol Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03218-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:05:49Z","timestamp":1767423949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3218"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03218-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal care and handling were performed in accordance with the guidelines of the Ajou University School of Medicine Institutional Animal Care and Use Committee (IACUC). All animal experiments were approved by the Institutional Animal Research Committee (2020-0043).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}